Judge Approves Cephalon’s $1.2B Accord With FTC

Overview


Jeffrey Brennan noted, regarding a Pennsylvania federal judge’s approval of an antitrust reverse-payment settlement in an FTC case against a pharmaceutical company, that if the case had gone to trial it would have been the first opportunity to see how the FTC would try a case following the Supreme Court’s Actavis ruling on this issue.